A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Status:
Recruiting
Trial end date:
2026-04-21
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand
therapy for patients with advanced or metastatic tumors that express proteins known as
integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5). The study will
also further characterize the radioligand imaging agent [68Ga]Ga-FF58 including its ability
to identify tumor lesions and its safety profile.